Drug intelligence / Profile preview

CSL412

Development stage: Phase 2
Lead developer: CSL
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

CSL412 is an adjuvanted influenza vaccine developed as a therapeutic vaccine for the prevention of human influenza. It utilizes the ISCOMATRIX adjuvant technology to enhance immune responses. The drug acts as an immunostimulant, aiming to boost the body's immune defense against influenza viruses. Its primary indication is for infectious diseases, specifically human influenza. The developer and manufacturer is CSL Limited[1][2].

Brand names: Panvax
Other names: CSL412 ISCOMATRIX FluCSL-412 ISCOMATRIX FluCSL 412 ISCOMATRIX Flu

Targets

Factor XIaC1R (Complement component 1r subcomponent)FXIIa (Coagulation Factor XIIa)C1S (Complement component 1s subcomponent serine protease)KLKB1 (Plasma kallikrein)

Beyond the preview

Go deeper on CSL412.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CSL412.

Explore the full profile